Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | RGS12 | O14924 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22164719 | 0.94 | MEN1 (0.57) | MEN1KMT2AMAPTUSP2POLB | |
| SCHEMBL29387419 | 0.94 | MEN1 (0.57) | MEN1KMT2AMAPTUSP2POLB | |
| SCHEMBL15559791 | 0.94 | MEN1 (0.57) | MEN1KMT2AMAPTUSP2POLB | |
| SCHEMBL17525431 | 0.94 | MEN1 (0.57) | MEN1KMT2AMAPTUSP2POLB | |
| SCHEMBL29389679 | 0.94 | MEN1 (0.57) | MEN1KMT2AMAPTUSP2POLB | |
| SCHEMBL17525430 | 0.94 | MEN1 (0.57) | MEN1KMT2AMAPTUSP2POLB | |
| SCHEMBL28765285 | 0.94 | MEN1 (0.57) | MEN1KMT2AMAPTUSP2POLB | |
| SCHEMBL17522967 | 0.91 | MEN1 (0.60) | MEN1KMT2AMAPTUSP2POLB | |
| SCHEMBL22181166 | 0.90 | MEN1 (0.58) | MEN1KMT2AMAPTUSP2POLB | |
| SCHEMBL17522979 | 0.85 | MEN1 (0.48) | MEN1KMT2AMAPTUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310813-A1 | DIMERIC NAPHTHALIMIDE COATING | Alucent Biomedical, Inc. (US) | 2023-10-05 | — | — | US | claimed |
| EP-4199903-A1 | DIMERIC NAPHTHALIMIDE COATING | Alucent Biomedical, Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| US-20220409608-A1 | DIMERIC NAPHTHALIMIDE FORMULATIONS | Alucent Biomedical, Inc. (US) | 2022-12-29 | — | — | US | claimed |
| EP-4051237-A1 | DIMERIC NAPHTHALIMIDE FORMULATIONS | Alucent Biomedical, Inc. (US) | 2022-09-07 | — | — | EP | claimed |
| WO-2022040402-A9 | DIMERIC NAPHTHALIMIDE COATING | Alucent Biomedical, Inc. (US) | 2022-04-14 | — | — | WO | claimed |
| WO-2022040402-A1 | DIMERIC NAPHTHALIMIDE COATING | Alucent Biomedical, Inc. (US) | 2022-02-24 | — | — | WO | claimed |
| US-20230405351-A1 | STERILIZABLE CATHETER AND LIGHT FIBER FOR USE THEREWITH AND METHODS OF STERILIZATION | ALUCENT BIOMEDICAL INC (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2023239950-A1 | COATED BALLOON CATHETER FOR TREATING ARTERIOVENOUS FISTULA AND METHODS FOR USING SAME | ALUCENT BIOMEDICAL INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239948-A1 | STERILIZABLE NVS CATHETER AND LIGHT FIBER FOR USE THEREWITH AND METHODS OF STERILIZATION | ALUCENT BIOMEDICAL INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230398334-A1 | COATED BALLOON CATHETER FOR TREATING ARTERIOVENOUS FISTULA AND METHODS OF USING SAME | ALUCENT BIOMEDICAL INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230310813-A1 | DIMERIC NAPHTHALIMIDE COATING | Alucent Biomedical, Inc. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4199903-A1 | DIMERIC NAPHTHALIMIDE COATING | Alucent Biomedical, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20230089273-A1 | METHODS FOR MATURING AN ARTERIOVENOUS FISTULA | Alucent Biomedical, Inc. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220409608-A1 | DIMERIC NAPHTHALIMIDE FORMULATIONS | Alucent Biomedical, Inc. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-4096658-A1 | STENT AND STENT DELIVERY FOR VASCULAR SURGERY | Alucent Biomedical, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4051237-A1 | DIMERIC NAPHTHALIMIDE FORMULATIONS | Alucent Biomedical, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022040402-A9 | DIMERIC NAPHTHALIMIDE COATING | Alucent Biomedical, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022040402-A1 | DIMERIC NAPHTHALIMIDE COATING | Alucent Biomedical, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409608-A1 | DIMERIC NAPHTHALIMIDE FORMULATIONS | NDC1, PKD1, FNTA | MEN1 1442/4885KMT2A 600/4885MAPT 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.